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758Background: Lung ischemia–reperfusion injury remains a significant problem after lung transplantation. Cas-
pase-mediated apoptotic pathways play an important role in lung ischemia–reperfusion injury, and caspase-3
is presumed to be the ‘‘effector’’ protease in the apoptotic cascade. Silencing gene expression of caspase-3 by
short hairpin RNA (shRNA) can downregulate the caspase cascade. Therefore, we evaluated the therapeutic ef-
ficacy of caspase-3 shRNA in a rat model of lung ischemia–reperfusion injury.
Methods: Lung ischemia–reperfusion injury was induced in rats by clamping the hilum of the left lung for 1 hour.
In vivo delivery of caspase-3 shRNA was performed by intratracheal administration 48 hours before ischemia. As
controls, animals received either scrambled shRNA or RNase-free 5% dextrose in water solution. Real-time poly-
merase chain reaction, Western blotting, and immunohistochemistry were used to assess the gene silencing effi-
cacy. The therapeutic effects of shRNA were evaluated by lung function analysis and the ratio of wet/dry weight.
Results: In this study, we have shown that ischemia–reperfusion injury is associated with an increased level of
lung caspase-3 messenger RNA. Animals treated with caspase-3 shRNA showed a significant downregulation in
lung expression of caspase-3 at transcripts and protein levels. Lung function was protected by caspase-3 shRNA
therapy, inasmuch as levels of partial pressure of oxygen and carbon dioxide were significantly increased and re-
duced, respectively.
Conclusions: In summary, we have demonstrated the therapeutic potential of shRNA to knock down the expres-
sion of caspase-3 and prevent lung apoptotic injury. Our findings may have some potential therapeutic relevance
for treating lung ischemia–reperfusion injury after transplantation.(J Thorac Cardiovasc Surg 2010;139:758-64)Lung ischemia–reperfusion injury (IRI) is a major complica-
tion observed after lung transplantation.1 Both clinical and
experimental data demonstrate that transplant IRI has delete-
rious short- and long-term effects, manifesting as increased
episodes of acute rejection and chronic allograft dysfunc-
tion.2 Despite refinements in lung preservation and improve-
ments in surgical techniques and perioperative care, lung IRI
remains a significant cause of early morbidity and mortality
after lung transplantation.3
Studies on single-lung transplantation in rodents showed
that almost no apoptosis was detected after cold or warm is-
chemia alone for up to 5 hours. After 6 to 12 hours, the
mode of alveolar epithelial cell death was dominated by apo-
ptosis in the ischemic preserved lung on reperfusion.5 Apopto-
sis at the alveolar epithelium became prominent after
reperfusion only.6 Furthermore, the number of apoptotic cells
increased with longer periods of reperfusion. Fischer and asso-oracic Surgery, Zhongshan Hospital Fudan University, Shanghai, China.
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The Journal of Thoracic and Cardiovascular Surgciates5 examined the presence and extent of apoptosis in lung
tissue biopsy specimens obtained from 20 consecutive human
lungs for transplantation; they indicated that 21% of cells
were apoptotic at 60 minutes after reperfusion and 34%
were apoptotic at 120 minutes after reperfusion. Apoptosis
of the ischemic alveolar epithelial cells was found to peak at
2 hours after reperfusion and to decrease after prolonged re-
perfusion.7 However, when the ischemic time was prolonged
up to 18 hours without reperfusion, a high percentage of cell
necrosis was observed.5,7 Physiologic changes associated
with lung IRI are increased microvascular permeability,
edema formation, and impaired gas exchange, especially
within the first 72 hours.3 On the basis of our previous studies,
we found that the level of caspase-3 messenger RNA (mRNA)
had started to increase half an hour after reperfusion, and the
peak of maximal caspase-3 activity occurred at 2 hours after
reperfusion. Therefore, this time point was selected for analy-
sis of the relationship between caspase-3 and lung IRI.
Although many inhibitors of apoptosis have been used to
reduce organ damage, the results have not been encouraging.
Short hairpin RNA (shRNA) is a powerful tool that can be
used to silence gene expression in mammalian cells. Recent
studies have shown that systemic administration of shRNA
can prevent local gene expression.8,9 For example, intrapor-
tal administration of caspase-3 and caspase-8 siRNA
(shRNA without vectors) can inhibit the expression of these
two proteins and attenuate warm liver IRI.10 Administrationery c March 2010
Abbreviations and Acronyms
CMV ¼ cytomegalovirus
D5 W ¼ 5% dextrose in water
IRI ¼ ischemia–reperfusion injury
mRNA ¼ messenger RNA
PaCO2 ¼ partial pressure of arterial carbon
dioxide
PaO2 ¼ partial pressure of arterial oxygen
PBS ¼ phosphate-buffered saline solution
PCR ¼ polymerase chain reaction
ShRNA ¼ short hairpin RNA
TUNEL ¼ TdT-mediated dUTP-biotin nick
end-labeling
W/D ¼ wet/dry weight ratio
Zhang et al Cardiothoracic Transplantationof caspase-3 and caspase-8 by hydrodynamic injection can
knock down the expression of the two caspases and prevent
acute renal injury.11 However, preventing lung IRI by using
shRNA to silence caspase-3 gene has not been reported yet.
The aim of this study was to evaluate the efficacy of cas-




Eighteen male Sprague–Dawley rats, weighing 230 to 260 g, were used.
They were obtained from Shanghai Laboratory Animal Centre of China
Academy of Sciences. All care and handling of animals were carried out
in accordance with guidelines contained in the ‘‘Guide for the Care and
Use of Laboratory Animals by Fudan University.’’
Caspase-3 shRNA Design
Oligonucleotide complementary DNA inserts encoding shRNA specific
for caspase-3 were designed using the Insert Design Tool available at the
public Web site (www.protocol-online.org). The oligonucleotides were
annealed and ligated into the PGCsi-U6/neo/GFP vector (GeneChem,
Shanghai, China) containing a modified cytomegalovirus (CMV)
promoter for RNA polymerase-II–mediated transcription. Caspase-3
shRNA oligonucleotides (top strand, 50-GATCCC-CAGCTAACCTCAG
AGAGACAT-TTCAAGAGA-ATGTCTCTCTGAGGTTAGCTG-TTTT
TGGAT-30; bottom strand, 50-AGCTATCCAAAAA-CAGCTAACCTC
AGAGAGACAT-TCTCTTGAA-ATGTCTCTCTGAGGTTAGCTG-GG-
30) contained a region specific to caspase-3 mRNA, a hairpin loop region,
and 50 and 30 linker sequences for subcloning into the BamHI and HindIII
sites of the PGCsi-U6/neo/GFP-CMV vector. The scrambled negative
control shRNA oligonucleotides contained identical hairpin loop and
linker sequences but a sequence of DNA not complementary to any
known rat gene (50- GGATCCGAGCTCGGTACCAAGCTT-30). The
newly created shRNA and scrambled shRNA vectors were prepared from
individual bacterial colonies. Correct orientation and location of the
oligonucleotides cloning were confirmed by sequencing.
Experimental Design and In Vivo Gene Silencing
Animals were randomized into 3 experimental groups (6 animals per
group). All rats were subjected to IRI. Before IRI experiments, animalsThe Journal of Thoracic and Cawere received shRNA or solution. In vivo gene silencing was performed
on the basis of a previously reported intratracheal injection method.12 In
brief, 48 hours before ischemia was performed, group 1 animals received
30 mg caspase-3 shRNA, group 2 received 30 mg scrambled (non-sense)
shRNA, and group 3 received 100 mL RNase-free 5% dextrose in water
(D5 W) solution, which was used to dilute the shRNA based on a previous
report.13 The solution group was set as a control.
Lung IRI Model and Surgical Procedure
Animals were anesthetized with an intraperitoneal injection of 3% pen-
tobarbital sodium (50 mg/kg) and placed on a heating pad to maintain their
body temperature during the operation. All rats underwent 1 hour of ische-
mia of the left lung followed by 2 hours of reperfusion. After intubation, rats
were mechanically ventilated with a volume ventilator (Harvard Inspira
ASV; Harvard Apparatus Inc, Holliston, Mass) in a pressure-controlled
mode at a fractional inspired oxygen concentration of 50% and inspira-
tory/expiratory ratio of 1:2. Peak inspiratory pressure was at 10 cm H2O
and positive end-expiratory pressure was set at 3 cm H2O. Frequency was
set at 40 breaths/min to maintain normocapnia.
After intubation, an anterolateral left-sided thoracotomy was performed
through the fifth intercostal space. A small rib retractor was placed to visu-
alize the lung hilum after luxation of the left lung to the posterior side. Is-
chemia was induced by clamping the hilum of the left lung in the inflated
state (3 cm H2O positive end-expiratory pressure) with an occluding micro-
vascular clamp without further dissection. During the ischemic period, the
rib retractor was removed and the incision was covered with a moist tissue
to minimize evaporation loss.
After 1 hour of ischemia, the clamp was removed and a reperfusion pro-
cedure was performed in all animals. Meanwhile, a peak inspiratory pres-
sure and positive end-expiratory pressure of 15 and 5 cm H2O were
performed, respectively, lasting about 10 seconds until the ventilation and
blood recovered normally. Subsequently, ventilation was continued to the
end of the reperfusion period in the same mode as before treatment.
Throughout the whole experiment, rats were placed on a heating pad to pre-
vent cooling, and rectal temperature was held constant in the normal range.
The animals received 0.9% sodium chloride, 0.5 mL/h, during the reper-
fusion period. At the end of the reperfusion period, blood gas values were
recorded in 0.4-mL heparinized blood taken from the left pulmonary vein.
Then a left pneumonectomy was performed immediately. The lung was
cut into several parts and then stored in 10% formaldehyde, torrefied for
72 hours at 70C, and fixed in 2% glutaraldehyde and 4% paraformalde-
hyde, respectively, while the remaining part was frozen in liquid nitrogen
for later analysis. Finally, the rats were humanely killed by exsanguinations
and an overdose of pentobarbital administered intravenously.Quantitative Polymerase Chain Reaction (Real-Time
PCR)
RNA was extracted from lungs using TRIzol reagent (Invitrogen Corpo-
ration, Carlsbad, Calif) according to the manufacturer’s protocol. RNA con-
centration was estimated from absorbance at 260 nm. Complementary DNA
was synthesized using oligo(dT) primer and reverse transcriptase (TaKaRa).
The following paired primers were used to detect beta-actin: 50-AACCC
TAAGGCCAACCGTGAAAA-30 (forward) and 50-CGACCAGAGGCA
TACAGGGACAA-30 (reverse); capase-3: 50-GTCTGACTGGAAAGCC
GAAACTCT-30 (forward) and 50-GAACCATGACCCGTCCCTTGAA-30
(reverse). Real-time PCR was performed with SYBR Premix Ex Taq
(TaKaRa) and 0.2 mmol/L of gene-specific primers. The PCR reaction
conditions were 95C for 10 seconds, 95C for 5 seconds, 60C for 20 sec-
onds, and 65C for 15 seconds (40 cycles).
Western Blotting
Lung homogenates were prepared from frozen lungs (80C) using cell
lysis buffer (20 mmol/L Tris pH 7.5, 150 mmol/L NaCl, 1% Triton X-100rdiovascular Surgery c Volume 139, Number 3 759
FIGURE 1. Western blotting and real-time polymerase chain reaction
(PCR) analysis of caspase-3 expression. The efficacy of gene silencing
was examined at the level of protein and mRNA, using Western blotting
and real-time PCR. A, The protein expression of caspase-3 was reduced sig-
nificantly in animals subjected to caspase-3 shRNA. The relative quantity of
caspase-3 mRNA for animals treated with caspase-3 shRNA was signifi-
cantly reduced, as shown in B (*P ¼ .008 shRNA vs scrambled, *P ¼
.007 shRNA vs solution, P<.01). No significant difference between scram-
bled shRNA and RNase-free 5% dextrose in water solution groups was
demonstrated. Data of the relative quantity of mRNA was expressed as
means  SEM, statistical significance as compared between caspase-3
shRNA and scrambled shRNA or RNase-free D5W solution.
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X(Union Carbide Corporation, Danbury, Conn), 2.5 mmol/L sodium pyro-
phosphate, 1 mmol/L ethylenediaminetetraacetic acid, 1% Na3VO4, 0.5
mg/mL leupeptin, 1 mmol/L phenylmethanesulfonyl fluoride). The lysates
were clarified by centrifugation at 12,000g for 5 minutes at 4 C. Protein,
40 mg, was separated by 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresus and analyzed for caspase-3 (Abcam, Cambridge, United
Kingdom) expression by immunoblot analysis. Immunoreactivity was de-
tected by enhanced chemiluminescence.
Histopathology and Immunohistochemistry
Examination
For histopathologic examination, lungs were collected, fixed in 10%
formaldehyde, sectioned, and stained with hematoxylin and eosin.
For immunochemistry, lung paraffin sections were fixed and incubated
with a 1:25 dilution of rabbit monoclonal antibody against caspase-3 (Ab-
cam). After being washed with phosphate-buffered saline solution (PBS),
the slides were incubated with rabbit HRP and developed with ready-to-
use 3,30-diaminobenzidine for 1 to 3 minutes and counterstained with
hematoxylin. Both antibody incubations lasted for 30 minutes at room
temperature.
Immunohistochemical staining was evaluated independently by two pa-
thologists with appropriate negative and internal positive controls. A semi-
quantitative evaluation was used to determine positive expression according
to the staining intensity: 0 for no staining (negative), 1 for mild staining, 2
for moderate staining, and 3 for intense staining; cell positive rates of less
than 25%, 25% to 50%, 50% to 75%, and greater than 75% were graded
as 1, 2, 3, and 4, respectively. The combination of staining intensity and pos-
itive expression rate was as follows: 0 (), 1 to 4 (þ), 5 to 8 (2þ), and 9 to 12
(3þ).
Electron Microscopy
Electron microscopy was performed as previously described.14,15 The rat
lungs were fixed in 2% glutaraldehyde and 4% paraformaldehyde solution
overnight at 4C. Four 1- to 2-mm cubes of the tissues were obtained at ran-
dom. Each sample was then postfixed in 1% potassium-ferrocyanide–
reduced osmium tetroxide for 2 hours at 4C, dehydrated in a series of
graded ethanol solution, cleared in propylene oxide, and embedded in epoxy
resin. Semithin sections (1 mm thick) were cut and stained with 0.5% tolu-
idine blue for light microscopy and then stained with lead citrate and uranyl
acetate before they were observed and photographed in a blind manner with
a JEOL 1200EX electron microscope (JEOL Ltd, Tokyo, Japan).
Assessment of Lung Function
Blood samples were obtained from the left pulmonary vein to monitor
lung function. Blood gas values, especially partial pressure of arterial oxy-
gen and carbon dioxide (PaO2 and PaCO2) were measured. Wet/dry weight
ratio (W/D) was used to assess lung edema.
TUNEL Assay
TdT-mediated dUTP-biotin nick end-labeling (TUNEL) methods were
used to detect the apoptotic alveolar epithelial cells, especially type II alve-
olar epithelial cell, as previously described.16,17 Assay was performed ac-
cording to the manufacturer’s protocol (Keygen KGA-703, Nanjing,
China). In brief, lung paraffin sections were deparaffinized, rehydrated, pre-
treated for 30 minutes at room temperature with 20 mg/mL proteinase K in
PBS for digestion of nuclear protein, quenched for 10 minutes at room tem-
perature with 3% H2O2 in methanol, rinsed in PBS, and subsequently incu-
bated for 60 minutes in a humidified atmosphere at 37C with TUNEL
reaction solution I. This solution consisted of TdT buffer containing 4 mL
TdT enzyme and 1 mL biotin-11-dUTP. Then the sections were rinsed in
PBS again and subsequently incubated for 30 minutes with TUNEL reaction
solution II, which consisted of 0.5 mL streptavidin–horseradish peroxidase
at the same situation as before. The TUNEL reaction was stopped by immer-760 The Journal of Thoracic and Cardiovascular Surgsion in PBS for 15 minutes at 37C. Sections were then incubated for 30
minutes at room temperature with a peroxidase-conjugated antidigoxigenin
antibody at a dilution of 1:50, using 3,30-diaminobenzidine as the chromo-
gen and hematoxylin as the counterstain. Negative controls for TUNEL la-
beling were performed by omission of the TdT enzyme. For quantification
of TUNEL signals, a minimum of 25 high-power fields were viewed per
sample, and the number of apoptotic nuclei per high-power field (apoptotic
index) was recorded.RESULTS
Effects of Caspase-3 Gene Silencing Using shRNA In
Vivo
Previous study, which used an intratracheal injection
method to administer siRNA, has demonstrated gene silenc-
ing in vivo in the lung.12 Accordingly, we used the same
method to deliver caspase-3 shRNA into the lung in vivo.
The efficacy of gene silencing was examined at the level
of mRNA, using real-time PCR. As shown in Figure 1, B,
the relative quantity of caspase-3 mRNA in the caspase-3
shRNA group was significantly reduced relative to other
groups that were treated with scrambled shRNA or RNase-ery c March 2010
FIGURE 2. Immunohistochemical analysis of caspase-3 protein expression. Immunohistochemistry was used to analyze the expression of caspase-3 at the
level of protein. Positive staining of caspase-3 (brown deposit) was observed in the cytoplasm of the alveolar epithelial cells of IRI lungs, as shown in black
arrows. A and B, Animals treated with RNase-free 5% dextrose in water (D5W) solution and scrambled shRNA, respectively. As shown, rats treated with
caspase-3 shRNA (C) showed significant reduction of brown deposit in the cytoplasm. No significant differences between scrambled shRNA and RNase-free
D5W solution groups were demonstrated.
Zhang et al Cardiothoracic Transplantationfree D5 W solution (P ¼ .008 shRNA vs scrambled, P ¼
.007 shRNA vs solution, P<.01). Western blotting and im-
munohistochemistry were used to analyze the expression of
caspase-3 at the protein level. Positive staining of caspase-3
(brown deposit) was observed in the cytoplasm of the alve-
olar epithelial cells of nonsilenced IRI lungs. In contrast, rats
treated with caspase-3 shRNA showed significant reduction
in protein level of caspase-3 by both Western blotting and
immunohistochemistry (P ¼ .011 shRNA vs scrambled, P
¼ .041 shRNA vs solution, P < .05; Figure 1, A, and
Figure 2). No significant differences between scrambled
shRNA and RNase-free D5 W solution groups were demon-
strated (P¼ .78, P>.05; Figures 1 and 2). Data are shown in
Table 1.TABLE 1. Semiquantitative results of immunohistochemical staining
for different group are shown
þ 2þ 3þ Total
Solution 0 3 3 6
Scrambled 1 2 3 6
shRNA* 4 2 0 6
Total 5 7 6 18
Rank sum test was used to analysis the data. The results showed that rats treated with
caspase-3 shRNA showed significant reduction in protein level of caspase-3 by immu-
nohistochemistry (*P ¼ .011 shRNA vs scrambled; *P ¼ .041 shRNA vs solution,
P < .05). No significant difference between scrambled shRNA and RNase-free
dextrose in water solution groups were demonstrated (P ¼ .78, P> .05).
The Journal of Thoracic and Ca
XCaspase-3 shRNA Protects IRI Lung From Lung
Dysfunction
To confirm that caspase-3 shRNA could lessen pulmonary
damage caused by apoptosis in IRI, we measured levels of
PaO2 and PaCO2 and W/D of the lung from the rats 2 hours after
reperfusion. As shown in Figure 3, animals treated with cas-
pase-3 shRNA before the hilum of the lung was blocked sig-
nificantly prevented the decrease of PaO2 and the increase of
PaCO2 2 hours after IRI (P< .01). W/D also decreased for
rats treated with caspase-3 shRNA (P< .01), which meant
that the lung edema was alleviated after treated with cas-
pase-3 shRNA. Hence, caspase-3 shRNA significantly attenu-
ated pulmonary damage induced by ischemia and reperfusion.
Furthermore, we examined the histopathologic changes in
the IRI lungs by electron microscopy. Lungs from rats that
were treated with scrambled shRNA or RNase-free D5 W
solution were severely damaged by ischemia and reperfu-
sion, as observed by swelling of mitochondrion, outer mem-
brane breaks, and intracristal dilation (Figure 4). In contrast,
lungs from rats that were pretreated with caspase-3 shRNA
were protected from IRI and seemed almost normal, exhib-
iting only mild pulmonary congestion.TQuantification of Apoptotic Cells During IRI
TUNEL analysis was used to detect the apoptotic alveolar
epithelial cells, especially type II alveolar epithelial cell.rdiovascular Surgery c Volume 139, Number 3 761
FIGURE 3. Caspase-3 shRNA protects lung function from IRI. We measured levels of PaO2 and PaCO2 and wet/dry weight (W/D) of the lung from the rats
2 hours after reperfusion. A, The level of PaO2 in animals treated with caspase-3 shRNA before blocking the hilum of the lung significantly prevented the
decrease of PaO2 (*P<.01). The level of PaCO2 shown in B significantly increased in animals subjected to caspase-3 shRNA (*P<.01). W/D also decreased
for rats treated with caspase-3 shRNA (*P< .01), which meant that the lung edema was alleviated after treatment with caspase-3 shRNA, as shown in C.
FIGURE 4. Electron microscopic observation of apoptotic expression. A and B, RNase-free 5% dextrose in water solution or scrambled shRNA treatment
group. Animals were observed for the presence of swelling of mitochondrion, outer membrane breaks, and intracristal dilation, as shown by black arrows. A,
In the caspase-3 shRNA treatment group, the expression of swelling of mitochondrion and intracristal dilation wasn’t obvious.
Cardiothoracic Transplantation Zhang et al
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FIGURE 5. Quantification of apoptotic cells during ischemia–reperfusion injury. TUNEL analysis was used to detect the apoptotic alveolar epithelial cells.
TUNEL staining (brown deposit) indicated that animals treated with caspase-3 shRNA showed fewer apoptotic cells than those treated with scrambled shRNA
or RNase-free 5% dextrose in water (D5W) solution (P<.05). The percentage of positive cells of caspase-3 shRNA (C) was 0.049 0.006 (n¼ 6), inasmuch
as 0.097  0.010 (n ¼ 6), and 0.098  0.037 (n ¼ 6) belonged to scrambled shRNA (B) and RNase-free D5W solution (A), respectively.
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XTUNEL staining indicated that animals treated with caspase-
3 shRNA showed fewer apoptotic cells than those treated
with scrambled shRNA or RNase-free D5 W solution (P
¼ .040 shRNA vs scrambled, P ¼ .038 shRNA vs solution,
P < .05). The percentage of positive cells of caspase-3
shRNA was 0.049  0.006 (n ¼ 6), as 0.097  0.010 (n
¼ 6) and 0.098  0.037 (n ¼ 6) belonged to scrambled
shRNA and RNase-free D5Wsolution, respectively. Data
are shown in Figure 5.
DISCUSSION
Lung IRI is a significant clinical problem in thoracic sur-
gery and particularly lung transplantation. Lung dysfunction
after lung transplantation is a frequently observed phenom-
enon that is associated with lung IRI. After lung transplanta-
tion, severe life-threatening graft dysfunction occurs in up to
30% of patients, related to IRI.4 Recent studies have shown
that apoptosis is involved in lung IRI and is thought to sig-
nificantly contribute to the development of primary acute
graft failure, which is the main cause for early mobility
and mortality after lung transplantation, resulting in a 1-
year survival of less than 80%.18 Lung IRI can also increase
pulmonary vascular permeability, cause alveolar epithelial
cell damage, and cause death of lung epithelial tissue, whichThe Journal of Thoracic and Camay contribute to pulmonary dysfunction seen after lung
transplantation.4,19
Experimental and clinical studies have shown that the
process of IRI is mediated largely by apoptotic pathways
and caspase activation. Blocking caspase-associated activa-
tion of apoptotic pathways from surface death receptors,
such as Fas, may attenuate IRI.20,21 It has been shown
that the loss of Fas can lessen organ damage.22 Caspase-
3 is a downstream effector component of the apoptotic
progress.23 Thus, we chose caspase-3 as potential therapeu-
tic target for prevention of lung IRI. Although many inhib-
itors of apoptosis have been used for preventing IRI, no
specific therapy is available to improve the clinical out-
come of IRI. Therefore, a new therapeutic strategy is
needed.
RNAi is a process through which double-stranded RNA
induces the activation of cellular pathways, leading to potent
and selective silencing of genes with homology to the double
strand. This approach overcomes many of the shortcomings
previously experienced with approaches such as antibodies,
antisense oligonucleotides, and pharmacologic inhibitors.
On the basis of this technique, we demonstrated that intratra-
cheal administration of caspase-3 shRNA inhibits the ex-
pression of caspase-3 and attenuates IRI of the lung. Inrdiovascular Surgery c Volume 139, Number 3 763
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shRNA can be delivered into most alveolar epithelial cells
after intratracheal administration.
Prevention of alveolar epithelial cell apoptosis in our stud-
ies produced a significant improvement of lung function af-
ter reperfusion. In addition, animals given caspase-3 shRNA
had better histologic profiles than did control animals given
scrambled shRNA or solution.
In summary, we have proved that intratracheal adminis-
tration of caspase-3–specific shRNA can inhibit lung cas-
pase-3 expression and prevent lung IRI. Consequently, the
method of caspase-3 shRNA delivery may represent a novel
approach to preventing apoptotic damage in lung IRI and
may become useful for clinical therapy.
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